Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Capital Expenditures: 2013-2020

Historic Capital Expenditures for Larimar Therapeutics (LRMR) over the last 6 years, with Dec 2020 value amounting to $397,000.

  • Larimar Therapeutics' Capital Expenditures rose 694.00% to $397,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $510,000, marking a year-over-year increase of 436.84%. This contributed to the annual value of $515,000 for FY2024, which is 214.02% up from last year.
  • Latest data reveals that Larimar Therapeutics reported Capital Expenditures of $397,000 as of Q4 2020, which was up 7,840.00% from $5,000 recorded in Q3 2020.
  • Larimar Therapeutics' Capital Expenditures' 5-year high stood at $400,000 during Q1 2016, with a 5-year trough of $1,000 in Q1 2018.
  • In the last 3 years, Larimar Therapeutics' Capital Expenditures had a median value of $23,500 in 2018 and averaged $65,100.
  • As far as peak fluctuations go, Larimar Therapeutics' Capital Expenditures spiked by 1,381.48% in 2016, and later slumped by 97.69% in 2017.
  • Over the past 5 years, Larimar Therapeutics' Capital Expenditures (Quarterly) stood at $260,000 in 2016, then crashed by 97.69% to $27,000 in 2017, then plummeted by 55.56% to $12,000 in 2018, then skyrocketed by 316.67% to $50,000 in 2019, then soared by 694.00% to $397,000 in 2020.
  • Its last three reported values are $397,000 in Q4 2020, $5,000 for Q3 2020, and $58,000 during Q1 2020.